Stockscreener 앱 받기
4.34
0.23%
0.010
시간 외 거래:
4.34
전일 마감가:
$4.33
열려 있는:
$4.3
하루 거래량:
11,016
Relative Volume:
0.29
시가총액:
$68.54M
수익:
-
순이익/손실:
-
주가수익비율:
-6.1196
EPS:
-0.7092
순현금흐름:
-
1주 성능:
-7.06%
1개월 성능:
+8.77%
6개월 성능:
+100.93%
1년 성능:
+132.09%
1일 변동 폭
$4.30
$4.46
1주일 범위
$4.30
$4.85
52주 변동 폭
$1.001
$5.87
알테리티 테라퓨틱스 Stock (ATHE) Company Profile
ATHE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATHE
Alterity Therapeutics Ltd Adr
|
4.34 | 68.54M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.37 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
513.54 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.32 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
537.92 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
252.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
알테리티 테라퓨틱스 Stock (ATHE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-03 | 다운그레이드 | The Benchmark Company | Speculative Buy → Hold |
| 2024-12-12 | 개시 | Maxim Group | Buy |
알테리티 테라퓨틱스 주식(ATHE)의 최신 뉴스
Alterity Therapeutics highlighted at MSA Congress - Investing.com
Alterity Therapeutics highlighted at MSA Congress By Investing.com - Investing.com India
Alterity Therapeutics reports Phase 2 data at MSA Congress - Investing.com
Alterity Therapeutics reports Phase 2 data at MSA Congress By Investing.com - Investing.com South Africa
Alterity shares new phase 2 data on MSA treatment - Investing.com
Alterity shares new phase 2 data on MSA treatment By Investing.com - Investing.com India
Alterity Therapeutics announces regulatory notice - Investing.com
Alterity Therapeutics completes placement - Investing.com
Alterity Therapeutics announces regulatory notice By Investing.com - Investing.com UK
Alterity Therapeutics completes placement By Investing.com - Investing.com UK
ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
Alterity Concludes Open-Label Trial Patient Visits - Investing.com
Alterity Therapeutics announces compliance notice - Investing.com
Alterity Therapeutics Issues Over 1 Billion New Shares - TipRanks
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Alterity Therapeutics raises A$40M in placement - TipRanks
Alterity secures funding to advance MSA drug development - Investing.com India
JPMorgan Ceases Substantial Holding in Alterity Therapeutics - TipRanks
Alterity Therapeutics announces trading halt - Investing.com
Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement - TipRanks
JPMorgan Becomes Substantial Holder in Alterity Therapeutics - TipRanks
Alterity Therapeutics reports compliance with Takeovers Panel By Investing.com - Investing.com South Africa
Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com
Alterity Therapeutics Discloses Equity Derivative Positions of Point72 - TipRanks
Alterity Therapeutics announces securities notice - Investing.com
Alterity Therapeutics Completes Significant Share Issuance - TipRanks
Alterity Therapeutics Quotes Over 164 Million Securities on ASX - TipRanks
Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN
Alterity Therapeutics Announces Major Securities Placement - TipRanks
Alterity Therapeutics Secures Funding to Advance Neurodegenerative Drug Development - TipRanks
Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434 - TipRanks
Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks
Predictive Oncology Inc (NASDAQ: POAI) Stock Is A Good Option To Consider - Stocks Register
Alterity Therapeutics reports quarterly activities - Investing.com
Alterity Therapeutics reports quarterly activities By Investing.com - Investing.com UK
Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data - TipRanks
Alterity Therapeutics Expands ASX Quoted Securities - TipRanks
Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks
Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline - TipRanks
Opthea reports positive Phase 1b DME trial results - Investing.com
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead
Alterity Therapeutics to join Maxim Healthcare Summit - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire
ASE Technology Holding Co., Ltd. American Depositary Shares (each representing (NY: ASX - Financial Content
A Full List of Australia ADRs - Investing.com Australia
알테리티 테라퓨틱스 (ATHE) 재무 분석
알테리티 테라퓨틱스 (ATHE)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
2.32%
0.98%
자본화:
|
볼륨(24시간):